JPRN-UMIN000015858Completed未知
A Phase II Study of SI-613 in Patients with Knee Osteoarthritis (repeat-dose study) - A Phase II Study of SI-613 in Patients with Knee Osteoarthritis (repeat-dose study)
SEIKAGAKU CORPORATIO0 sites160 target enrollmentStarted: December 11, 2014Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 160
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 40years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •-Patients with secondary OA resulting from trauma or other diseases -Patients with risk of infection in the area of the injection site due to skin disease or infection.
Investigators
Similar Trials
Completed
Phase 2
A Phase II Study of SI-613 in Patients with Knee OsteoarthritisKnee OsteoarthritisJPRN-UMIN000010167SEIKAGAKU CORPORATIO120
Completed
Phase 3
A Phase III Study of SI-613 in Patients with Knee Osteoarthritis (confirmatory study)Knee osteoarthritisJPRN-jRCT2080223482SEIKAGAKU CORPORATIO440
Unknown
Phase 2
Study of SI000413 in Knee Osteoarthritis PatientsOsteoarthritis, KneeNCT01525758Dong-A Pharmaceutical Co., Ltd.152
Completed
Phase 2
Intra-articular Injection of Allogenic Lyophilized Growth Factors in Primary Knee OsteoarthritisOsteo Arthritis KneeNCT04331327Rasmia Elgohary31
Completed
Not Applicable
Health outcomes following SYNVISC-ONE in Knee OsteoarthritisACTRN12616001504404The University of Queensland130